Public market insider buying at Zomedica Pharmaceuticals (:ZOM)

Johnny Powers, a Director, acquired 625,000 Common Shares on a direct ownership basis at a price of $0.160USD on July 1st, 2020. This represents a $136,280 investment into the company's shares and an account share holdings change of greater than 100%.

Zomedica Pharmaceuticals is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Zomedica Pharmaceuticals Corp is a development stage veterinary diagnostic and pharmaceutical company. The Company is engaged in developing products for companion animals, such as canine, feline, and equine by focusing on needs of clinical veterinarians. It is focused on developing three diagnostic platforms, a Bulk Acoustic Wave sensor-based veterinary point-of-care diagnostic platform for performing immunodiagnostic testing, a Raman spectroscopy-based point-of-care diagnostic platform for the detection of pathogens, and liquid biopsy assays for the detection of cancer, along with related consumables. The Company's TRUFORMA product candidate is an investigational device being developed as a point-of-care biosensor platform. ZM-020 is its diagnostic platform being developed to screen for a range of pathogens in companion animal feces, urine, respiratory, and dermatological samples. It is developing ZM-017 as a canine cancer liquid biopsy platform.